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I M M U N O L O G Y
A single-nucleotide polymorphism in a  
Plasmodium berghei ApiAP2 transcription factor  
alters the development of host immunity
Munir Akkaya1*, Abhisheka Bansal2†, Patrick W. Sheehan1‡, Mirna Pena1, Alvaro Molina-Cruz2, 
Lindsey M. Orchard3, Clare K. Cimperman1, Chen-Feng Qi1, Philipp Ross3§, Takele Yazew1, 
Daniel Sturdevant4, Sarah L. Anzick4, Girija Thiruvengadam2||, Thomas Dan Otto5, 
Oliver Billker6,7, Manuel Llinás3,8, Louis H. Miller2, Susan K. Pierce1*
The acquisition of malaria immunity is both remarkably slow and unpredictable. At present, we know little about 
the malaria parasite genes that influence the host’s ability to mount a protective immune response. Here, we 
show that a single-nucleotide polymorphism (SNP) resulting in a single amino acid change (S to F) in an ApiAP2 
transcription factor in the rodent malaria parasite Plasmodium berghei (Pb) NK65 allowed infected mice to mount 
a T helper cell 1 (TH1)–type immune response that controlled subsequent infections. As compared to PbNK65S, 
PbNK65F parasites differentially expressed 46 genes, most of which are predicted to play roles in immune evasion. 
PbNK65F infections resulted in an early interferon- response and a later expansion of germinal centers, resulting 
in high levels of infected red blood cell–specific TH1-type immunoglobulin G2b (IgG2b) and IgG2c antibodies. Thus, 
the Pb ApiAP2 transcription factor functions as a critical parasite virulence factor in malaria infections.
INTRODUCTION
Malaria is an infectious disease caused by parasites of the genus 
Plasmodium. In humans, the most deadly parasite, Plasmodium falciparum, 
is responsible for the deaths of nearly 400,000 individuals a year, 
mostly young African children. A recent report by the World Health 
Organization concluded that the progress achieved over recent years 
in reducing global malaria cases and deaths appears to have stalled 
(1). At present, there is no effective malaria vaccine and the need for 
one is all the more acute. A better understanding of the host-parasite 
interactions that influence the host’s ability to mount a protective 
immune response would aid in the development of an effective vaccine.
In previously unexposed individuals, blood-stage P. falciparum 
parasites rapidly replicate and induce fever and other symptoms 
of malaria, mediated by the parasite-induced production of pro- 
inflammatory cytokines, including interferon- (IFN-) and tumor 
necrosis factor– (TNF-), and chemokines by both innate immune 
cells and CD4+ T cells (2–5). Although responsible for the disease 
symptoms, this inflammatory response is critical for the control of 
blood-stage parasites (6, 7). Over time in malaria endemic areas, 
individuals eventually acquire protective antibodies that control blood- 
stage parasites. Thus, control of parasites in humans has two phases: an 
immediate inflammatory response upon infection and a longer-term 
process of acquiring protective antibodies following repeated infec-
tions. In nonlethal Plasmodium infections in mouse models, two 
similar phases, namely, an early IFN-–mediated control of blood-
stage parasitemia followed by the later acquisition of protective 
antibodies, have been demonstrated (8–10). In lethal Plasmodium 
infections, these protective mechanisms are presumably not adequately 
induced, resulting in failure to control blood-stage parasitemia. At 
present, we have an incomplete understanding of the mechanisms 
that regulate the ability of Plasmodium parasites to induce the early 
inflammatory and later antibody responses in the host. Recent evi-
dence suggests that Plasmodium parasites may disable the host’s 
immune response through dysregulation of B cell and CD4+ T cell 
functions (11, 12), although specific mechanisms have yet to be 
demonstrated. This raises the question: does the Plasmodium par-
asite genome encode genes that function to control the host immune 
response, analogous to virulence factors in other pathogens. Cur-
rently, there are only a few examples of candidate virulence genes 
(13, 14) and our understanding of the mechanisms by which such 
genes function is incomplete.
Here, we report on the impact of a single-nucleotide polymorphism 
(SNP) between the rodent parasites P. berghei (Pb) NK65 and PbANKA 
on the ability of mice to mount a protective immune response to 
infection. This SNP is in the gene that encodes a member of the 
apicomplexan homolog of plant Apetela2 (ApiAP2) transcription 
factor (TF) family. There are only 20 SNPs in the coding regions of 
the genes of PbNK65 and PbANKA parasites (14). It is remarkable 
that the two parasites differ in so few SNPs considering the extreme 
differences in the diseases they cause. PbNK65 infections result in 
anemia in mice that, with time, is lethal but not directly immune 
mediated. In contrast, PbANKA infections result in severe cerebral 
malaria that rapidly kills mice in a CD8+ T cell–dependent process. 
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Thus, in the evolution of Plasmodium, these SNPs may have had a 
profound effect. Most of the 20 PbNK65/PbANKA SNPs were in 
genes of unknown function. ApiAP2 was of interest because, as a 
TF, it likely controlled the expression of a variety of genes. We 
hypothesized that the PbNK65/PbANKA SNP in the gene encoding 
ApiAP2 may be a good candidate for a parasite virulence factor that 
controls host immune responses.
There are 26 members of the ApiAP2 TF family, and despite 
their similarities, each has unique features in terms of their DNA 
recognition motifs and their expression patterns during the life cycle 
of Plasmodium, suggesting distinct functional properties (15–17). 
PBANKA_011210 (referred to here as ApiAP2) is a Pb ApiAP2 family 
member predominantly expressed in schizonts in the blood stage of 
the parasite infection in mice and appears to be essential as Pb par-
asites, in which the gene encoding ApiAP2 was knocked out, were 
not viable (18). Consequently, we have little knowledge of the func-
tions that are dependent on the expression of this TF. Recent com-
parative genetic screening of rodent Plasmodium strains (14, 19) 
revealed a nonsynonymous SNP (a T-to-C transition at position 5468) 
in the first DNA binding domain of the ApiAP2 gene. This SNP 
resulted in a phenylalanine (F) in PbANKA and PbSP11 strains and 
a serine (S) in PbNK65 and PbK173 strains at amino acid position 
1823 of the ApiAP2 protein. Given that this polymorphism is located 
in the ApiAP2 DNA binding domain and that the biochemical dif-
ferences between phenylalanine, a hydrophobic aromatic amino acid, 
and serine, a hydrophilic amino acid, we postulated that these two 
genes may encode functionally different ApiAP2 proteins.
Here, we provide evidence that the two polymorphic forms of 
ApiAP2 do bind to different DNA motifs, resulting in altered tran-
scriptional profiles, and that infections of mice by PbNK65F versus 
PbNK65S result in markedly different host immune responses, one 
that is protective and one that is not. Thus, this ApiAP2 is a Pb vir-
ulence factor.
RESULTS
The SNP in the DNA binding domain of Pb ApiAP2 alters its 
sequence specificity
We confirmed by DNA sequencing the presence of the SNP (T in 
PbANKA and C in PbNK65-NYU at position 5468) in our laboratory 
clones of PbANKA and PbNK65-NYU (fig. S1A). We cloned the 
sequences encoding the first AP2 DNA binding domain of each 
polymorphic form, expressed the genes in Escherichia coli, purified 
the proteins, and tested their DNA binding specificity using DNA 
binding microarrays composed of custom-made DNA sequences. 
The highest-scoring target DNA motifs for ApiAP2S and ApiAP2F 
were different: GGGCTTAA and GGGACTTA, respectively (Fig. 1A) 
(data file S1). To investigate the functional consequences of this 
ApiAP2 polymorphism, we generated PbNK65 parasites that differed 
only in the T5468C SNP using CRISPR-Cas9 (fig. S1, B and C). The 
whole-genome sequence analysis of wild-type (WT) PbNK65 and 
CRISPR-edited PbNK65 parasites confirmed that the only 10 SNP 
regions that were consistently different between the two parasites 
were the target-specific alterations generated by the CRISPR strategy. 
This included nine silent mutations generated by the guide sequence 
and one missense mutation, resulting in the desired S-to-F alteration 
(table S1). SNPs that were observed only in a fraction of reads of 
the same gene were excluded, as alternate sequences were similarly 
present in both parasites.
We refer to the PbNK65 strain that carries C at nucleotide position 
5468 resulting in an S at amino acid position 1823 in the ApiAP2 
protein as PbNK65S and, conversely, the PbNK65 strain that has a T 
at position 5468 resulting in an F at position 1823 in the ApiAP2 
protein as PbNK65F. We infected mice with either PbNK65F or 
PbNK65S and carried out an RNA-sequencing (RNA-seq) analysis on 
blood drawn from each when parasitemias reached approximately 
10% and the distributions of various blood-stage forms were com-
parable. A principal components analysis of the data showed that the 
transcriptomes of the PbNK65S and PbNK65F parasites overlapped 
(Fig. 1B). However, a detailed RNA-seq analysis showed differential 
expression of 46 Plasmodium genes, 40 of which were down-regulated 
in PbNK65F compared to PbNK65S (Fig. 1C). Among these differ-
entially expressed 46 genes, 22 belonged to the interspersed repeat 
(IR) of the Berghei IR (BIR) gene family (Fig. 1D). The Plasmodium 
IR family (PIR), the largest gene family in Plasmodium, consists of 
subtelomeric genes that are thought to encode proteins expressed on 
the infected red blood cell (iRBC) surface and play a major role in 
antigenic variation in the parasite (20). The RNA-seq data also showed 
differences in the expression levels of Plasmodium genes belonging 
to three additional gene families, fam-a (7 of 46), fam-b (8 of 46), and 
fam-c (2 of 46) (Fig. 1D). These genes, like the BIRs, are expressed 
predominantly in blood stage and are thought to be exported to the 
iRBC surface and possibly play roles in invasion, antigenic variation, 
and immune evasion (14, 21, 22).
We carried out a genome-wide analysis to determine whether the 
DNA binding motifs of ApiAP2S and ApiAP2F were present in the 
promoter regions of the differentially expressed genes identified by 
RNA-seq. Because of high redundancy in the first and the eighth 
nucleotides of the identified DNA binding motifs (Fig. 1A), we 
focused on the middle six nucleotides and tested the presence of 
these two motifs within the promoter regions arbitrarily defined as 
the 1500 base pairs (bp) before the start site of each gene, in all genes 
in the Pb genome. This algorithm identified 113 possible binding 
sites for ApiAP2S and 75 for ApiAP2F in the promoters of the 46 
differentially regulated genes (data file S1). Thus, the ApiAP2S motif 
was in higher frequency as compared to the ApiAP2F motif. Among 
these 46 genes, 42 contained at least one ApiAP2S or ApiAP2F DNA 
binding motifs, providing a link between the SNP and the differential 
regulation of these genes. An in-depth analysis of the promoter 
regions that contained these motifs showed that although the distri-
bution of the two motifs within the promoters of all Pb genes was 
comparable (Fig. 1E), within the differentially expressed genes, 
the ApiAP2S motifs tended to be located more proximal to the tran-
scription start site as compared to the ApiAP2F motifs (Fig. 1F), 
suggesting possible differences in transcriptional regulation of these 
genes by ApiAP2S and ApiAP2F. Together, these analyses provide a 
link between the presence of the ApiAP2S and ApiAP2F DNA binding 
motifs in the promoter regions and the differential expression of these 
genes in PbNK65S and PbNK65F parasites.
PbNK65F parasites are able to complete both the sexual 
stages in the mosquito host and the pre-erythrocytic stage 
in the mouse
We determined whether the PbNK65F parasite was able to complete 
the full life cycle of the parasite. The cycle begins with the differen-
tiation of sexual-stage gametocytes in the mouse host that are taken up 
in a blood meal by mosquitoes. In the mosquito midgut, the gametes 
form oocysts that then develop into sporozoites, a highly motile form 
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of the parasite that accumulates in the mosquito salivary glands. The 
sporozoites are injected into the mouse host as the mosquito takes a 
blood meal and travel through the blood to the liver where they 
infect hepatocytes. In the liver, the sporozoites expand and differentiate 
to merozoites that exit the liver and begin the blood-stage infection, 
thus completing the life cycle. To determine whether the SNP in 
ApiAP2 affected the ability of the parasite to complete its life cycle, 
we devised an experimental model that included the sexual and 
pre-erythrocytic stages of the Pb infection (fig. S2A). Mice were 
infected with PbNK65S or PbNK65F (106 iRBCs intraperitoneally), 
and once the parasitemia reached approximately 1.2%, mosquitoes 
were fed on these mice. At 14 days after feeding, a subset of mos-
quitoes was dissected and the oocysts in midgut were evaluated both 
qualitatively (fig. S2B) and quantitatively (fig. S2C). A portion of 
the remaining mosquitoes were dissected at day 21 after feeding; 
sporozoites in their salivary glands were harvested and counted 
(fig. S2D). Sporozoites (5 × 103) were injected into uninfected mice, 
and the progression to liver-stage malaria was observed by harvesting 
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Fig. 1. ApiAP2F mutation alters the DNA sequence specificity of the PBANKA_011210 ApiAP2 protein. (A) DNA sequences that received the highest hit in DNA 
binding microarray analysis of the first domain of ApiAP2S- and ApiAP2F-mutated PBANKA_011210 ApiAP2 proteins. (B to D) PbNK65S or PbNK65F parasites were used to 
infect C57BL/6 mice. RNA-seq analysis was carried out from blood samples of infected mice. Principal components analysis (B), genes whose expressions were significantly 
altered between the two groups (C), and the pie chart representation of multigene families that these genes belong to (D) are shown. Numbers under bar graphs in 
(C) indicate the gene annotation in (PBANKA_######) format. Gene families for each gene are indicated in parenthesis. Pseudogenes are shown with asterisks. (E and 
F) Density graphs showing the relative distribution of the middle hexamer regions of DNA sequences in (A) in the 1500-bp promoter region of randomly sampled (E) or 
differentially regulated (F) genes.
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liver at 46 hours after injection and comparing the parasite levels by 
quantitative polymerase chain reaction (qPCR) (fig. S2E). None of 
these parameters showed variation between PbNK65S and PbNK65F. 
Last, the Plasmodium-infected mosquitoes were fed on uninfected 
mice, and the progression of disease was observed. While notable 
experimental variation existed in disease progression either due to 
the inability to control the inoculum size or due to an unidentified 
difference in sporozoite function, all infected mice eventually devel-
oped blood-stage infection, as confirmed by repeated parasitemia 
checks (data not shown). These findings indicate that the SNP in 
the ApiAP2 does not prevent the completion of the full plasmodium 
life cycle.
Infection with PbNK65F drives a strong TH1-type  
immune response
To explore the impact of the SNP in ApiAP2 on the outcome of 
blood- stage infection, we infected mice with either PbNK65S- or 
PbNK65F-infected RBCs at 106 parasites per mouse. The hemoglobin 
levels, parasitemias, and survival for mice infected with the two dif-
ferent parasites were similar (Fig. 2, A to C). All mice died because 
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Fig. 2. PbNK65F infection leads to stronger IFN- and TNF- responses in infected mice. (A to C) C57BL/6 mice were infected with either PbNK65F or PbNK65S using 
106 iRBCs per mouse delivered intraperitoneally. Changes in survival (A), parasitemia (B), and hemoglobin levels (C) were monitored during the course of infection. Each 
circle represents an individual mouse. Data represent three independent experiments each carried out with at least 10 animals per group. (D) Sera collected at different 
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of severe anemia between days 20 and 26 after infection, with para-
sitemias between 30 and 60% and hemoglobin levels below 3 g/dl. To 
characterize the early immune response in PbNK65S- and PbNK65F- 
infected mice, we collected sera on days 3, 7, 11, 15, and 19 after 
infection and assayed these for various cytokines and chemokines 
(Fig. 2D). The serum levels of IFN-, the master enhancer of T helper 
cell 1 (TH1) differentiation, were higher in PbNK65F-infected mice 
as compared to PbNK65S-infected mice, peaking on day 7 after in-
fection. Similarly, on day 7 after infection, the levels of interleukin-1 
(IL-1) and TNF-, cytokines that also enhance TH1 cell differenti-
ation, were higher in PbNK65F-infected mice. Conversely, on day 7 
after infection, the levels of the proinflammatory regulators and 
chemoattractants such as CXCL-1, CCL3, CCL4, MCP-1, and RANTES 
were higher in PbNK65S-infected mice as compared to PbNK65F- 
infected mice. With time after infection, the levels of CCL4 became 
equivalent in the two groups of mice and continued to increase through 
day 19 after infection. For CCL3, MCP-1, RANTES, and CXCL-1, 
as the infection progressed to day 19 after infection, the level of these 
cytokines tended to reverse and increased more in PbNK65F-infected 
mice as compared to PbNK65S-infected mice. Levels of IL-10 and 
IL-12 p40 were also increased with infection but were not significantly 
different between the two groups of mice (fig. S3).
Infection with PbNK65F results in a persistent adaptive 
immune response
To characterize the immune response to infection by PbNK65F and 
PbNK65S, we collected spleens of the mice at day 6, 10, 15, or 19 
after infection and quantified the total numbers of germinal center 
(GC) B cells (Fig. 3A), B cells of the plasma cell (PC) lineage (Fig. 3B), 
and follicular helper T (TFH) cells (Fig. 3C) using the gating strategy 
outlined in fig. S3A. The numbers of GC B cells, PC lineage cells, 
and TFH cells peaked similarly around day 10 to 15 after infection in 
both PbNK65S- and PbNK65F-infected mice. However, in the late 
stage of the infection on day 19 after infection, although all three cell 
populations decreased in numbers in both PbNK65S- and PbNK65F- 
infected mice, the numbers of GC B cells, PC lineage cells, and TFH 
cells were significantly higher in PbNK65F-infected mice as compared 
to PbNK65S-infected mice, indicating a more persistent immune 
response (Fig. 3, A to C). We also assessed the total number of CD8+ 
T cells, as well as the numbers of CD8+ effector memory and central 
memory T cells 10 and 19 days after infection and observed no 
differences in these numbers in PbNK65S-infected versus PbNK65F- 
infected mice (fig. S3B).
To determine whether the persistent increases in GC B cells, PC, 
and TFH in response to PbNK65F infections were dependent on 
IFN-, we compared responses to infection by either PbNK65S or 
PbNK65F in IFN-–deficient mice (IFNKO mice) and WT mice at 
day 19 after infection. Although infections with PbNK65S and 
PbNK65F (106 parasites per mouse) were fatal in both mouse 
strains, we observed differences in the expansion of GC B cells, PC 
lineage cells, and TFH cells in IFNKO mice as compared to WT mice 
19 days after infection. In IFNKO mice, PbNK65F infection resulted 
in fewer GC B cells, PC lineage B cells, and TFH cells as compared to 
PbNK65S infection (Fig. 3, D to F), a reversal of the phenomenon 
observed in infection of WT mice (Fig. 3, A to C). Thus, the ability 
of PbNK65F infections to expand lymphocyte populations was 
IFN- dependent. In addition, we observed differences in the mag-
nitude of the expansion of cells in WT versus IFN- knockout (KO) 
mice (Fig. 3, D to F) that may be explained by the immunomodula-
tory role of B cell–intrinsic IFN- signaling as recently shown by 
Guthmiller et al. (23).
The splenic architecture has been shown to be disrupted in the 
acute blood stage of malaria, primarily due to a combination of 
the burden of iRBC in the spleen and erythropoiesis (24–26). We 
carried out a histopathological evaluation of spleens taken from 
PbNK65S- and PbNK65F-infected mice. On day 10 after infection, 
the spleens of PbNK65S- and PbNK65F-infected mice were similar 
with well-organized B cell follicles, as visualized by double staining 
with CD4- and B220-specific antibodies (Fig. 4, A and C). Numerous 
peanut agglutinin (PNA)–stained GC foci with proliferative activity 
(Ki-67+) were also present in mice infected with PbNK65S and PbNK65F. 
However, at the late stage of infection, 19 days after infection, sig-
nificant disruption of the B cell follicle structure was observed in 
PbNK65S-infected mice with no visible B-T organization, no typi-
cal GCs, and no proliferative activity (Fig. 4, B and C). In contrast, 
in PbNK65F-infected mice, B-T organization, GCs, and prolifera-
tive activity persisted, consistent with the flow cytometry data indi-
cating a prolonged cellular response (Fig. 4, B and C).
Having observed a more persistent GC B cell and PC response 
in PbNK65S-infected versus PbNK65F-infected mice, we measured 
the levels of total and iRBC-specific immunoglobulin M (IgM) and 
IgG at days 7 and 19 after infection (Fig. 5A). The sera obtained 
on days 7 and 19 after infection showed similar levels of total IgM 
in PbNK65S- and PbNK65F-infected mice (Fig. 5A). However, on 
day 19 after infection, the levels of total IgG were significantly higher 
in the PbNK65F-infected mice compared to PbNK65S-infected mice 
(Fig. 5A). We also measured the levels of IgM and IgG that bound 
to lysates of uninfected RBCs or to lysates prepared from either 
PbNK65F- or PbNK65S-infected RBCs. Antibody reactivity against 
uninfected RBC lysate was observed, indicating a degree of autore-
activity consistent with earlier reports (fig. S4A) (27, 28). However, 
the levels of uninfected RBC binding antibodies were around 1/5 to 
1/10 of the level of iRBC binding antibodies. We subtracted the 
values obtained from uninfected RBC lysate–coated wells from the 
values acquired from the corresponding iRBC lysate–coated wells 
and presented these values (Fig. 5, B to G). The levels of iRBC- 
specific IgM were similar between mice infected with PbNK65S 
or PbNK65F on both days 7 and 19 after infection (Fig. 5B). In con-
trast, the iRBC-specific IgG was significantly higher on day 19 after 
infection (but not on day 7 after infection) in PbNK65F-infected 
mice as compared to PbNK65S-infected mice regardless of the source 
of the iRBC lysate (Fig. 5C). The higher total levels of iRBC-specific 
IgG reflected increases in the levels of IgG2b (Fig. 5E) and IgG2c 
(Fig. 5F) but not of IgG1 (Fig. 5D) or IgG3 (Fig. 5G), indicating a 
predominant TH1-type immune response to the PbNK65F parasites, 
consistent with the observation of an early TH1-type inflammatory 
response. Differences in anti-iRBC antibody levels between PbNK65F- 
and PbNK65S-infected mice may reflect increases in antibodies 
against the same parasite target molecules and/or differential ex-
pression of immunogenic molecules between the parasite strains, 
leading to different antibody repertoires.
Reduction in parasite burdens in PbNK65F infections, but not 
in PbNK65S infections, allows development of  
protective immunity
Having observed that lethal infection of mice with PbNK65F resulted 
in immune responses late in the infection just before death of the 
mice, we determined whether reducing the parasite burden during 
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the initial infection would allow protective immunity to fully develop 
in PbNK65F-infected mice and promote survival. We reduced the 
parasite burden by either treating infected mice with a nonsterilizing 
dose of chloroquine (Fig. 6, A to D) or by reducing the parasite 
inoculum (Fig. 6, E to G).
For chloroquine-mediated reduction in parasite load, as depicted 
(Fig. 6A), mice were infected with either PbNK65S or PbNK65F, the 
infections were allowed to progress for 8 days, and parasitemias 
were quantified by flow cytometry and confirmed blood smears. At 
day 8 after infection, mice were randomly divided into two groups 
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that were either left untreated or treated daily for 8 days with the 
anti-malarial chloroquine at nonsterilizing doses. Survival and par-
asite levels were followed until day 75 after infection. In the absence 
of chloroquine, the parasite levels increased in both PbNK65S- and 
PbNK65F-infected mice, reaching high levels (Fig. 6B), resulting in 
the death of all the mice by day 23 (Fig. 6C). The 8-day chloroquine 
treatment reduced the parasitemia to nearly undetectable levels 
in both PbNK65S- and PbNK65F-infected mice (Fig. 6B). Once the 
daily chloroquine treatment was stopped, on day 16 after infection, 
recrudescent parasitemias were not controlled in most PbNK65S- 
infected mice and reached high levels (Fig. 6B), resulting in the 
death of 80% of the mice by day 40 after infection (Fig. 6C). In con-
trast, most PbNK65F mice controlled the recrudescent parasitemia, 
maintaining it at low levels (Fig. 6B), resulting in survival of over 
90% of these mice (Fig. 6C).
To determine whether PbNK65F-infected, chloroquine-treated 
mice that survived developed protective immunity, in a parallel ex-
periment, we challenged a group of the surviving mice, which were 
free of parasite as confirmed by blood smear at day 37 after infection, 
with either PbNK65F or PbNK65S parasites (Fig. 6D). Age-matched 
mice that did not receive the first infection but were treated or 
not with chloroquine served as controls (Fig. 6D and fig. S4B). All 
infected control mice died by day 27 after infection (Fig. 6D). In 
contrast, 100% of mice that survived the first infection by PbNK65F 
following chloroquine treatment survived the challenge infection with 
PbNK65F and 60% were protected against challenge with PbNK65S. 
Repeated experiments confirmed these findings despite slight alter-
ations in the duration of chloroquine treatment required to suffi-
ciently limit parasitemia. Thus, PbNK65F infections in which the 
parasite burden was reduced resulted in complete protection against 
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challenge with PbNK65F and partial protection to the highly related 
PbNK65S strain.
We reduced the parasite burden by reducing the parasite inoculum 
(Fig. 6, E to G). We first titrated the dose of iRBC from 106 to 101 
in 10-fold increments to determine whether there was a dose of 
iRBCs at which PbNK65F-infected mice survived and PbNK65S- 
infected mice did not. We found that this occurred at a dose of 102 
iRBCs per mouse and that, above this dose, both infections were 
lethal and, below this dose, mice survived both infections. At a dose 
of 102 iRBC per mouse, 70% of the PbNK65F-infected mice did not 
develop detectable levels of parasitemia (Fig. 6E), and these mice 
survived the infection (Fig. 6F). In contrast, all of the PbNK65S- 
infected mice developed parasitemias (Fig. 6E), and none of these 
mice survived. Thus, mice were able to mount a protective response 
against the PbNK65F parasites but not against PbNK65S. Moreover, 
survival of the PbNK65F infection was dependent on IFN-, as 
in IFNKO mice, parasitemias were not controlled in PbNK65S and 
PbNK65F infections and all mice died (fig. S4C). This finding is 
consistent with the observation that PbNK65F infections resulted 
in higher IFN- responses as compared to PbNK65S infections at 
day 7 after infection.
To ensure that the differential progression of disease between 
PbNK65F- and PbNK65S-infected mice was dependent on the adap-
tive immune response and not due to intrinsic growth properties 
of the parasites, we infected WT mice and mice deficient in RAG-2 
(RAG-2KO) that lacked an adaptive immune system. In RAG-2KO 
mice, the parasitemias in PbNK65S and PbNK65F infection pro-
gressed similarly to high levels (Fig. 6G). Thus, the ability to control 
parasitemia in the low-inoculum PbNK65F infection was lost in 
RAG-2KO mice.
DISCUSSION
Malaria continues to be a serious global health problem, affecting 
over 200 million people each year and causing over 400,000 deaths 
annually in Africa alone (29). At present, we do not have an effective 
malaria vaccine and a clear understanding of the genetic factors that 
govern Plasmodium virulence would likely contribute to development 
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of a vaccine. Here, we provided evidence that a single SNP in the 
AP2 DNA binding domain of the TF ApiAP2 is a virulence factor in 
the mouse malaria parasite PbNK65. Mice are not able to mount 
a protective immune response to PbNK65S parasites and develop 
high parasitemias and die even at low-inoculum infections (100 par-
asites per infection). In contrast, PbNK65F infections induce an early 
IFN- response and a later expansion of GC B cells, PCs, and TFH 
cells, resulting in high levels of iRBC-specific TH1-type IgG2b and 
IgG2c antibodies. The expansion of B cells, PCs, and TFH and the 
ability to survive low-inoculum infections are IFN- dependent, as 
shown in IFN-KO mice.
In terms of possible mechanisms by which expression of ApiAP2F 
confers the ability of PbNK65F to induce a protective immune re-
sponse, we showed that the nonsynonymous SNP altered the target 
DNA sequence of ApiAP2F, resulting in the differential expression 
of 46 Pb genes in the blood-stage infection. Although the individual 
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functions and expression patterns of these genes are largely unknown, 
comparative genomic analyses predict expression on the RBC surface 
and thus involvement in host-pathogen interactions (14, 20). Twenty- 
two of the 46 differentially expressed genes are members of the BIR/
PIR family that are thought to play an important role in antigenic 
variation on the iRBC surface. The expression of ApiAP2F resulted 
in the down-regulation of the transcription of the majority of these 
genes in PbNK65F infection. Thus, our data suggest that these BIR 
genes may play a role in either suppressing or evading the immune 
response in PbNK65S infections. Spence et al. (30) recently provided 
evidence that vector transmission intrinsically modified the asexual 
blood-stage infection of P. chabaudi chabaudi, resulting in an en-
hanced, protective immune response in mice. The attenuated viru-
lence of vector-transmitted P. chabaudi chabaudi was associated with 
increased expression of members of the CIR/PIR family. Thus, in 
this case, the PIR genes appear to be a target of the immune response. 
The role of these gene families in parasite virulence will require a 
better understanding of their function and expression.
Our results suggest that ApiAP2S expression is beneficial to the 
parasite in preventing protective immune responses in the infected 
host. The ApiAP2S SNP is highly conserved in ApiAP2 orthologs 
in almost all Plasmodium strains, including the human parasite 
P. falciparum. Moreover, the target DNA sequence we report here 
for domain 1 of ApiAP2S is also conserved in the AP2 domain of the 
P. falciparum ortholog, namely, PF3D7_0613800 (15), suggesting that 
the conservation of this SNP is due to the immune invasion benefit 
it confers on the parasite.
Conversely, ApiAP2F expression is presumably deleterious to the 
parasite, as its expression evokes a parasite-specific immune response 
in the host. Nevertheless, ApiAP2F is encoded in at least two strains 
of Pb (19). It is of interest that whole-genome sequencing of multi-
ple laboratory Plasmodium strains showed that parasite strains that 
differed in approximately 20 SNPs in their entire coding regions, in-
cluding in the ApiAP2 SNP described here, had dramatically differ-
ent outcomes in infection, resulting in severe anemia versus cerebral 
malaria (14). Understanding the relationship of the immune response 
to parasites expressing ApiAP2F in different parasite backgrounds 
and disease pathology will be of interest.
In conclusion, through in-depth functional characterization, we 
identify the ApiAP2 PBANKA_011210 as an important regulator of 
the Pb immune evasion machinery. To our knowledge, this is not 
only the first report of a role for any ApiAP2 family member in a 
mammalian host-pathogen interaction but also the first character-
ization of a functional role for an essential ApiAP2. The approach 
described here may facilitate functional characterization of other 
essential members of the ApiAP2 family for which KO parasites are 
not viable.
MATERIALS AND METHODS
Mice and reagents
For all animal experiments, age-matched, 7- to 9-week-old female 
mice were used. C57BL/6 mice were purchased from The Jackson 
Laboratory. RAG-2 KO and IFN- KO mice were purchased Taconic 
Farms. Mice were maintained at the National Institute of Allergy 
and Infectious Diseases animal facility according to Animal Care 
and Use Committee Standards.
Fluorescent-conjugated monoclonal antibodies against mouse 
CD45 [allophycocyanin (APC)], Ter119 (APC-Cy7), CD19 [phyco-
erythrin (PE)–Cy7], B220 (AF700), CD138 (PE), CD4 (BV605), 
CXCR5 (BV421), PD-1 (PE), CD8 (BV785), CD44 (AF700), and 
CD62L (PE-Dazzle 594) were purchased from BioLegend. Anti- 
mouse GL7 (e660) and CD95 (Percp-e710) were purchased from 
Thermo Fisher Scientific. Dead cells were excluded from flow cy-
tometry analyses using a LIVE/DEAD Near-IR dye (Thermo Fisher 
Scientific). Horseradish peroxidase (HRP)–conjugated antibodies 
against mouse IgG, IgG1, IgG2a, IgG3, and IgM were purchased 
from Jackson ImmunoResearch. HRP-conjugated anti-mouse IgG2c 
was purchased from SouthernBiotech. Chloroquine used in in vivo 
experiments were purchased from Sigma and used at a dose of 
10 mg/kg (intraperitoneally).
Infection of mice with parasitized RBCs
Parasites were grown from frozen infected RBC stocks in donor 
C57BL/6 mice. Peripheral blood parasitemia was checked using both 
blood smears and a flow cytometry–based strategy described else-
where (31). Once parasitemia in donor mice reached a 5 to 10% range, 
blood drawn from the donor was diluted in phosphate-buffered 
saline (PBS) and injected to the experimental mice (intraperitoneally) 
at 106 infected RBC per mouse unless otherwise noted. To avoid 
gradual changes in virulence by repetitive passaging of parasite, 
stocks prepared from comparable passage numbers were used. Pro-
gression of the blood-stage disease was monitored in the experimental 
mice by routine parasitemia checks as described above.
Construction of plasmid for editing AP2 (PBANKA_011210) 
in Pb NK65NYU
For editing the AP2 (PBANKA_011210) gene in Pb NK65NYU, re-
placing serine-1823 with phenylalanine (S1823F), we used the 
CRISPR-Cas9 system (32). A guide sequence of 20 nucleotides 
(5′-GCTGAATTAAAACCCCAAAG-3′), with protospacer adjacent 
motif (5′-AGG-3′), was selected by manual curation for targeting 
the Cas9 endonuclease to result in the desired editing (5467 TCT to 
TTT) in the AP2 gene. The 900 nucleotides of synthetic sequence 
(given in supplementary information 2) with the mutated guide 
region and the desired SNP (5467 TCT to TTT) were subcloned in 
the pYC plasmid using Nco I and Xho I restriction enzyme sites. 
The resulting plasmid, pYC_NK65AP2ANKA, was used for the trans-
fection of the Pb NK65NYU parasites.
Transfection of the Pb NK65NYU parasites
The Pb transfections were done as described earlier (33, 34). Briefly, 
a BALB/c mouse was infected with freshly revived frozen stock of 
Pb NK65NYU parasites. Two naïve BALB/c mice were injected in-
traperitoneally with the infected blood from the donor mouse 
(two to three drops of ~10% parasitemia). The mice were sacrificed 
once the parasitemia reached ~5%, and the parasites were allowed 
to develop in vitro to the mature schizont stage in RPMI 1640 
with l-glutamine, 25 mM Hepes, and hypoxanthine (50 g/ml; 
KD Medical, Columbia, MD), 28 ml of 7.5% sodium bicarbonate 
(KD Medical, Columbia, MD), and gentamicin (10 g/ml; Gibco, 
Thermo Fisher Scientific, Grand Island, NY) supplemented with 
20% fetal bovine serum. The mature schizont stage parasites were 
purified using Percoll purification method. The purified schi-
zonts were washed twice with RPMI 1640 solution (KD Medicals, 
Columbia, MD). The schizonts (106 to 107) were then resuspended 
in 100 l of the Nucleofector solution prepared from Amaxa Basic 
Parasite Nucleofector Kit 1 (Lonza, USA) containing 10 g of the 
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pYC_NK65AP2ANKA plasmid. The resuspended schizonts were 
transfected with Nucleofector II (Lonza, USA) using the program 
U33. The transfected parasites were mixed immediately with 100 l 
of RPMI 1640 solution and injected intravenously in a naïve BALB/c 
mouse. The drug-resistant parasites were selected with pyrimeth-
amine (0.7 mg/ml) and dissolved in the drinking water against the 
human dihydrofolate reductase selection marker in the transfected 
plasmid. The pyrimethamine treatment was continued for 1 week, 
and the drug-resistant parasites were screened for the presence of 
the desired SNP by DNA sequencing. The clonal parasite was gen-
erated by injecting 20 BALB/c mice with one parasite per mouse. 
The parasites were allowed to grow without pyrimethamine pres-
sure. Once visible in the Giemsa smears, the parasites were passaged 
three times through C57BL/6 mice for the final study of the SNP 
in AP2. The WT NK65NYU parasites were also cycled in the BALB/ 
c and C57BL/6 mice just like the edited parasites for comparative 
study.
Confirmation of editing in the AP2 gene (PBANKA_011210) 
of NK65NYU parasites by DNA sequencing
After the appearance of pyrimethamine-resistant parasites, the intro-
duction of SNP in the AP2 gene of NK65NYU was confirmed by DNA 
sequencing. The genomic DNA from the AP2-mutated NK65NYU 
(PbNK65F) parasites was amplified with the following primer pair 
outside the 900-bp homology arm: AP2F (5′-GATTATAGATACA-
AATAATGAGAAAATGGG-3′) and AP2R (5′-GCATATGTGATAG-
TGTTATTTCCATC-3′). The introduction of the SNP was confirmed 
with two sequencing reactions performed using internal primers, one 
in forward (primer AP2Seq1, 5′-CAATTATAATAATTTGAATGAA-
GGGGAAC-3′) and another in reverse direction (primer AP2Seq2, 
5′-GAGTAATCAAGAATCTCAAAATTGTGAT-3′).
To detect sequence inconsistencies between WT and CRISPR- 
modified samples, whole-genome sequencing was performed on 
TruSeq Nano (Illumina Inc.) paired-end libraries prepared from 
two WT (WT 81 and WT 83) and two mutant (AP2 76 and AP2 77) 
samples. Libraries were sequenced to a mean coverage of 172× on 
the NextSeq instrument using a 2× 150-cycle kit (Illumina Inc.).
Raw image files were converted to fastq files using bcl2fastq 
(v2.20.0.422, Illumina Inc., San Diego, CA), trimmed of adapter 
sequences, and quality-filtered for a minimum base quality score 
of 20 using cutadapt (v 1.12) (35) and FASTX (v 0.0.14) tools. Quality- 
trimmed reads were mapped to the Pb NK65e reference genome 
(assembly GCA_900088445.1) using Bowtie2 (version 2.2.9) (36). 
Bowtie2 default settings were used, with unpaired and discordant 
alignments suppressed. Reads were also mapped to mouse ref-
erence GRCm38/mm10 to assess contaminating mouse se-
quences. SAM files were converted to coordinate-sorted BAM 
files using SAMtools (37). Sequence read statistics are shown in 
table S1.
Duplicate reads were marked using Picard’s MarkDuplicates tool 
(v 2.18.7) (38), and variants were detected in multisample mode 
using SAMtools and BCFtools packages with -ploidy 1 (37). In 
SAMtools, --redo-BAQ was enabled in mpileup. SNPs and INDELs 
were extracted into separate VCF files using GATK SelectVariants, 
and then each VCF file was filtered for depth and quality using 
vcftools (v 0.1.15) and –min-meanDP 10 and –minQ 200 param-
eters. The filtered multisample vcf file was annotated using SNPeff 
(39). Variants were also detected using GATK HaplotypeCaller and 
Freebayes, which yielded similar results.
Variants detected in the same position across all four samples, 
due to differences from the NK65e reference genome, were removed 
from further analysis. INDEL calls were concordant across all four 
samples, indicating that there were no differences in WT and mutant 
genomes. Raw sequences were submitted to the National Center for 
Biotechnology Information (NCBI) Sequence Read Archive database 
(accession no.: PRJNA548804).
Protein binding microarrays
Each Pb AP2 domain was PCR-amplified from Pb genomic DNA 
and cloned into the pGEX-4T1 vector (GE Healthcare) using Bam HI 
and Xho I restriction sites to create a gene fusion resulting in an 
N-terminal glutathione S-transferase (GST)–tagged recombinant 
protein. Protein expression was induced with 0.2 mM isopropyl- -
d-thiogalactopyranoside (IPTG) at 37°C for 4 hours in BL21-Co-
donPlus(DE3)-RIL cells (Agilent Technologies). Protein purification 
was carried out using Glutathione-Superflow Resin (Clontech), 
as previously described (15) and verified by Coomassie blue 
staining.
Purified recombinant proteins were run on protein binding micro-
arrays (PBMs) to assess DNA binding activity, as previously described 
(15). Briefly, custom DNA microarrays (Agilent Technologies) were 
double-stranded, incubated with GST-tagged recombinant protein, 
incubated with Alexa 488–conjugated anti-GST antibody (Thermo 
Fisher Scientific, A11131), and scanned using an Axon 4300A scanner 
(Molecular Devices). Enrichment scores and position weight matrices 
(PWMs) were generated using seed-and-wobble algorithms from an 
earlier publication (40). Scores greater than 0.45 were considered 
significant and indicate specific binding.
Each GST-tagged protein was run on two PBM versions: AMADID 
016060 (v9) and AMADID 015681 (v11). Each version contains 
the same oligonucleotide probes in a different order. PWMs from 
the two arrays were combined to generate the final results (data 
file S1).
Analysis of PWMs generated by in vitro PBMs was used to scan 
Pb promoter regions. First, PWMs were trimmed to their six most 
informative base pairs, or their core motifs. PlasmoDB version 34 
(41) of the Pb ANKA reference genome and gene annotations were 
downloaded and used to generate promoters of 1500 nucleotides 
in length. Promoters were defined as 1500 bp upstream of the 
translation start site (ATG) of protein-coding genes only. These 
promoter regions were then scanned using FIMO version 4.12.0 
(42) and a motif hit significance threshold of 0.001. Data analysis 
was performed in R version 3.4.1 (https://www.r-project.org). 
Analysis code is available at https://github.com/pzross/pberghei_
ap2mutant.
Pb infection of mosquitoes
Anopheles stephensi female mosquitoes (5 to 6 days old) were infected 
with Pb by feeding on anesthetized infected C57BL/6 mice. The in-
fectivity of the mice was established by determining the parasitemia 
in a blood smear. In all the studies, mice having parasitemias be-
tween 1 and 3% parasitemia were used to infect mosquitoes. Blood- fed 
infected mosquitoes were kept at 20°C and 80% humidity. Pb midgut 
infection was quantified by light microscopy 11 days after blood 
feeding with mercurochrome staining (0.1% in water). Sporozoite 
load was determined in salivary glands 21 days after blood feeding. 
The salivary glands of mosquitoes were dissected in PBS, and pools 
of 9 or 10 pairs of glands were homogenized by passaging through a 
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27-gauge needle 15 times. Sporozoites were counted under the micro-
scope in a hemocytometer.
ELISA and serum cytokine analyses
To measure the relative amount of antibodies specific to parasite 
antigens, infected animals were bled at day 19 after infection. Blood 
was collected in anticoagulant tubes, spun down, washed with 
PBS, and then resuspended in approximately 4 ml of PBS. This 
solution was slowly added on top of a double Percoll gradient 
containing 40% Percoll (top) and 72% Percoll (bottom). Following 
ultracentrifugation, the middle layer containing enriched infected 
RBCs was harvested. Percoll was removed by washing the RBCs 
with RPMI mixed with 10× PBS at 10:1 and 20:1 ratios and RPMI 
alone for the first-second and third washes, respectively. iRBCs 
were pelleted and lysed in a buffer containing 100 mM tris (pH7.4), 
150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 
1% Triton X-100, 0.5% sodium deoxycholate, and protease in-
hibitor cocktail (Roche) for 20 min on ice. Lysed cells were diluted 
with equal amount of PBS at the end of the procedure. For control 
group, RBCs from uninfected mice were harvested and lysed simi-
larly. PBS solution containing 1:400 dilution of lysed RBC was 
used to coat Nunc Maxisorp enzyme-linked immunosorbent assay 
(ELISA) plates (Thermo Fisher Scientific). Upon overnight incu-
bation at 4°C, plates were washed and blocked with bovine serum 
albumin–containing solution. Diluted sera harvested from infected 
animals were added to the wells followed by washing and incu-
bation with HRP-conjugated secondary antibodies. Plates were 
developed using trimethylboron (TMB) solution, and reaction was 
terminated using 0.16 M H2SO4 solution. Plates were read at an op-
tical density of 450 nm using a SpectraMax plate reader (Molecular 
Devices). Arbitrary units were calculated using a standard curve 
generated by applying serial dilutions of a mixed serum sample 
onto infected RBC lysate–coated wells.
Cytokine levels in sera of the infected animals were measured using 
relevant LEGENDplex kits (BioLegend) according to the manu-
facturer’s guidelines.
Flow cytometry and histopathologic evaluation
For flow cytometry, samples were stained in Hanks’ balanced salt 
solution supplemented with 2% fetal calf serum, 1% Hepes, and 10 mM 
sodium azide (Sigma-Aldrich). Analyses were carried out using a 
BD LSR-2 or a BD X20 cytometer. Data analysis was carried out using 
FlowJo software. Gating strategy for identifying different cell sub-
sets was adapted from a previous study (43).
For histopathologic evaluation, spleens from infected mice were 
harvested at various time points after infection and immediately fixed 
in 10% formalin solution followed by embedding into paraffin. Tissue 
sections were either hematoxylin and eosin–stained or immunostained 
following a previously described protocol (44).
Quantitative reverse transcription PCR
Parasite loads in livers of sporozoite-injected (5 × 103 sporozoites per 
mouse, intravenously) mice were measured 45 hours after injection. 
Livers were flushed under anesthesia, and liver specimens were im-
mediately frozen in liquid nitrogen. Livers were homogenized in RLT 
buffer using 2.3-mm zirconia/slica beads (Biospec) under agitation 
in a Biospec bead beater. Homogenate was further passed through 
QIAShredder (Qiagen) columns, and RNA was isolated using the 
RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s 
guidelines. Complementary DNA (cDNA) synthesis was carried out 
using the iScript cDNA Synthesis Kit (Bio-Rad). qPCR was carried 
out using the IQ SYBR Green Kit (Bio-Rad). Pb 18S was amplified 
using two sets of primers: set 1 (5′-ATTAATCTTGAACGAG-
GAATGGCT-3′ and 5′-TCAATCGGTAGGAGCGACG-3′) and 
set 2 (5′-AAGCATTAAATAAAGCGAATACATCCTTAC-3′ and 
5′-GGAGATTGGTTTTGACGTTTATGTG-3′). Three housekeeping 
genes murine HPRT (5′-TGCTCGAGATGTGATGAAGG-3′ and 
5′-TCCCCTGTTGACTGGTCATT-3′), murine GAPDH (5′-GTG-
GAGTCATACTGGAACATGTAG-3′ and 5′-AATGGTGAAGGTC-
GGTGTG-3′), and murine PPIA (5′-TTCACCTTCCCAAAGAC-
CAC-3′ and 5′-CAAACACAAACGGTTCCCAG-3′) were used for 
normalization. Delta Ct values were calculated by subtracting the 
geometric mean of Ct values of the three housekeeping genes from 
the Ct value of 18S for each sample.
RNA sequencing
For RNA sequencing, 250 l of purified mouse cheek blood cells was 
mixed with 750 l of Trizol LS (Thermo Fisher Scientific) and RNA 
was isolated according to the manufacturer’s recommendations.
Twelve samples each containing 4 g of total RNA were treated 
with the Globin-Zero Gold rRNA Removal Kit (Illumina Inc.) fol-
lowed by TruSeq mRNA Sequencing Library Preparation (Illumina 
Inc.). The resulting single-indexed libraries were fragment-sized on 
a Bioanalyzer DNA1000 chip and quantitated using a Kapa Library 
Quant kit (Illumina) and Universal qPCR mix (Roche) to facilitate 
the creation of a normalized, 2 nM multiplexed pool. This multi-
plexed pool was clustered across two lanes of a RAPID flow cell at a 
concentration of 10 pM, followed by paired-end sequencing on an 
Illumina HiSeq 2500 for 100 cycles from each fragment end plus an 
additional 7 cycles to sequence the index.
Raw next generation sequencing (NGS) reads were processed by 
first removing any Illumina adapter sequences using Cutadapt 
v1.12 (35) and then trimmed and filtered for quality and length (min-
imum length of 35 bp) using FastX Tool Kit v0.0.14 (Hannon Lab, 
Cold Spring Harbor Laboratory). Trimmed reads for each replicate 
were then mapped using Hisat2 v2.0.5 (45) set to report only 
matched pairs. Final transcripts based on the combined replicates 
and then differentials for each comparison were generated using 
Deseq2 (10.18129/B9.bioc.DESeq2) for each experimental condition. 
RNA-seq data were uploaded to the NCBI Gene Expression Omnibus 
repository with the accession number GSE111333.
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